Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing
Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing
12/08/20, 12:15 PM
Location
cambridgeMoney raised
$81 million
Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing to address the underlying drivers of disease, launched today with $81 million in financing. The funds will support development of the company's REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics. The Series A round was led by Foresite Capital with participation from seed investors Atlas Venture and The Column Group. Additional investors joining the financing included Arch Venture and Alexandria Venture Investments.
Company Info
Location
cambridge, maryland, united states
Additional Info
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix's innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.
SOURCE Remix Therapeutics